Jennifer M Kwon Selected Research

Zolgensma

1/2022	Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.
1/2022	Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
10/2021	Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy.
1/2021	Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jennifer M Kwon Research Topics

Disease

5	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 01/2022 - 01/2021
3	Globoid Cell Leukodystrophy (Krabbe Disease) 01/2018 - 03/2016
2	Seizures (Absence Seizure) 04/2022 - 10/2008
2	Neuronal Ceroid-Lipofuscinoses (Neuronal Ceroid Lipofuscinosis) 02/2014 - 09/2013
1	Autoimmune Diseases of the Nervous System 04/2022
1	Thrombotic Microangiopathies 10/2021
1	Fever (Fevers) 01/2021
1	Hydrocephalus (Hydrocephaly) 01/2021
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2018
1	Adrenoleukodystrophy (Adrenoleukodystrophy, X-Linked) 01/2017
1	Muscular Diseases (Myopathy) 01/2016
1	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2016
1	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2014
1	Epilepsy (Aura) 02/2006
1	Autistic Disorder (Autism) 02/2006
1	Landau-Kleffner Syndrome 02/2006
1	Autism Spectrum Disorder 02/2006
1	Alcoholism (Alcohol Abuse) 09/2004
1	Depressive Disorder (Melancholia) 09/2004
1	Type 2B Charcot-Marie-Tooth disease 03/2003
1	Reinfection 03/2003
1	Foot Ulcer 03/2003
1	Infections 03/2003
1	Muscle Weakness 03/2003

Drug/Important Bio-Agent (IBA)

4	ZolgensmaIBA 01/2022 - 01/2021
2	GalactosylceramidaseIBA 01/2018 - 03/2016
1	RisdiplamIBA 01/2022
1	Prednisolone (Predate)FDA LinkGeneric 10/2021
1	Transaminases (Aminotransferases)IBA 01/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2016
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2016
1	Biological ProductsIBA 09/2013
1	CeroidIBA 09/2013
1	lipopigmentsIBA 09/2013
1	LipofuscinIBA 09/2013
1	Phenobarbital (Luminal)FDA Link 10/2008
1	Immunoglobulin G (IgG)IBA 02/2006
1	Immunoglobulin M (IgM)IBA 02/2006
1	AutoantibodiesIBA 02/2006
1	AntigensIBA 02/2006
1	Tuberculin (PPD)IBA 02/2006
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 02/2006
1	Histones (Histone)IBA 02/2006
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 09/2004
1	Proteins (Proteins, Gene)FDA Link 03/2003
1	Guanosine Triphosphate (GTP)IBA 03/2003

Therapy/Procedure

3	Therapeutics 04/2022 - 02/2014
2	Hematopoietic Stem Cell Transplantation 01/2017 - 12/2016
1	Critical Care (Surgical Intensive Care) 04/2022
1	Stem Cell Transplantation 01/2018
1	Transplantation 01/2018
1	Hormone Replacement Therapy (Therapy, Hormone Replacement) 01/2017
1	Surgical Amputation (Amputations) 03/2003